CN115605587B - 新型重组溶素及其在治疗革兰氏阴性菌感染中的用途 - Google Patents

新型重组溶素及其在治疗革兰氏阴性菌感染中的用途

Info

Publication number
CN115605587B
CN115605587B CN202180034907.8A CN202180034907A CN115605587B CN 115605587 B CN115605587 B CN 115605587B CN 202180034907 A CN202180034907 A CN 202180034907A CN 115605587 B CN115605587 B CN 115605587B
Authority
CN
China
Prior art keywords
gram
protein
ikb206
seq
negative bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180034907.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN115605587A (zh
Inventor
罗伯托·迪兹·马丁内斯
玛丽亚·莫拉莱斯·阿雷扎加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telum Therapy Co ltd
Original Assignee
Telum Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telum Therapy Co ltd filed Critical Telum Therapy Co ltd
Priority to CN202511878710.9A priority Critical patent/CN121422198A/zh
Publication of CN115605587A publication Critical patent/CN115605587A/zh
Application granted granted Critical
Publication of CN115605587B publication Critical patent/CN115605587B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01028—N-Acetylmuramoyl-L-alanine amidase (3.5.1.28)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180034907.8A 2020-03-11 2021-03-11 新型重组溶素及其在治疗革兰氏阴性菌感染中的用途 Active CN115605587B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511878710.9A CN121422198A (zh) 2020-03-11 2021-03-11 新型重组溶素及其在治疗革兰氏阴性菌感染中的用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20382177 2020-03-11
EP20382177.2 2020-03-11
EP20382254.9 2020-03-31
EP20382254 2020-03-31
PCT/EP2021/056264 WO2021180892A1 (en) 2020-03-11 2021-03-11 New recombinant lysin and its use in the treatment of gram-negative bacterial infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511878710.9A Division CN121422198A (zh) 2020-03-11 2021-03-11 新型重组溶素及其在治疗革兰氏阴性菌感染中的用途

Publications (2)

Publication Number Publication Date
CN115605587A CN115605587A (zh) 2023-01-13
CN115605587B true CN115605587B (zh) 2026-02-13

Family

ID=74859480

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180034907.8A Active CN115605587B (zh) 2020-03-11 2021-03-11 新型重组溶素及其在治疗革兰氏阴性菌感染中的用途
CN202511878710.9A Pending CN121422198A (zh) 2020-03-11 2021-03-11 新型重组溶素及其在治疗革兰氏阴性菌感染中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511878710.9A Pending CN121422198A (zh) 2020-03-11 2021-03-11 新型重组溶素及其在治疗革兰氏阴性菌感染中的用途

Country Status (8)

Country Link
US (2) US12655409B2 (cg-RX-API-DMAC7.html)
EP (1) EP4118192A1 (cg-RX-API-DMAC7.html)
JP (2) JP7863509B2 (cg-RX-API-DMAC7.html)
CN (2) CN115605587B (cg-RX-API-DMAC7.html)
AU (1) AU2021236351A1 (cg-RX-API-DMAC7.html)
CA (1) CA3175024A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011291A (cg-RX-API-DMAC7.html)
WO (1) WO2021180892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria
CN114774391B (zh) * 2022-03-09 2023-03-14 华南农业大学 一种抗大肠杆菌的噬菌体内溶素及其应用
WO2024231498A1 (en) * 2023-05-09 2024-11-14 BioNTech SE Intravaginal formulations of gardnerella endolysins
FR3149209B1 (fr) * 2023-06-02 2026-04-03 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
WO2024246325A1 (en) * 2023-06-02 2024-12-05 L'oreal Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol
CN121420063A (zh) * 2023-06-30 2026-01-27 国立大学法人 冈山大学 可穿透革兰氏阴性菌外膜的多肽、包含所述多肽的抗菌蛋白、抗菌剂或消毒剂、药物组合物、以及抗菌剂组合物或消毒剂组合物
TW202541833A (zh) * 2023-12-12 2025-11-01 德商拜恩技術股份公司 包含內溶素之組合物及其用途
CN118420716B (zh) * 2024-05-28 2025-10-31 青岛农业大学 一种多肽125、包含多肽125的生物材料及应用
WO2026139534A1 (en) * 2024-12-24 2026-07-02 Telum Therapeutics, S.L. Antibacterial peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111420037A (zh) * 2020-03-26 2020-07-17 中国农业科学院饲料研究所 噬菌体裂解酶Lysep3在制备广谱抗菌药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002959A2 (en) * 2008-07-03 2010-01-07 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
PL2445515T3 (pl) 2009-06-26 2016-10-31 Środki przeciwdrobnoustrojowe
JP5847081B2 (ja) 2009-08-24 2016-01-20 カトリック ユニバーシテイト ルーベン ケイ.ユー. ルーベン アール アンド ディー エンドリシンOBPgpLYS
RU2614114C2 (ru) 2010-09-17 2017-03-22 Текнифар-Индустриа Текника Фармасьютика, С.А Бактериофаги, фаговые пептиды и способы их применения
GB201018518D0 (en) 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
BR112016030580B1 (pt) 2014-06-26 2023-12-19 The Rockefeller University Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
ES2934714T3 (es) 2015-09-17 2023-02-24 Contrafect Corp Polipéptidos de lisina activos contra bacterias Gram-negativas
KR20240162610A (ko) * 2017-04-03 2024-11-15 사시나파스 컴퍼니 리미티드 조작된 그람-음성 엔도리신

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111420037A (zh) * 2020-03-26 2020-07-17 中国农业科学院饲料研究所 噬菌体裂解酶Lysep3在制备广谱抗菌药物中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Morita M等.Functional analysis of antibacterial activity of Bacillus amyloliquefaciens phage endolysin against Gram-negative bacteria.《FEBS Lett》.2001,(第500期),摘要,第1页第2.1节,图1,表1. *
putative endolysin [Enterobacter phage Arya];Tikhe C 等;《GeneBank》;20180813;Accession: YP_009284326 *
The antibacterial activity of E. coli bacteriophage lysin lysep3 is enhanced by fusing the Bacillus amyloliquefaciens bacteriophage endolysin binding domain D8 to the C-terminal region;Wang S 等;《J Microbiol》;20170126;第55卷(第5期);第403-408页 *
Tikhe C 等.putative endolysin [Enterobacter phage Arya].《GeneBank》.2018,Accession:YP_009284326. *

Also Published As

Publication number Publication date
US20260226444A1 (en) 2026-08-06
JP2023517245A (ja) 2023-04-24
JP2026041893A (ja) 2026-03-10
US12655409B2 (en) 2026-06-16
MX2022011291A (es) 2022-12-08
WO2021180892A1 (en) 2021-09-16
CN115605587A (zh) 2023-01-13
JP7863509B2 (ja) 2026-05-21
AU2021236351A1 (en) 2022-10-06
US20230138922A1 (en) 2023-05-04
EP4118192A1 (en) 2023-01-18
CN121422198A (zh) 2026-01-30
CA3175024A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
JP7863509B2 (ja) 新たな組換え溶解素及びグラム陰性細菌感染の治療におけるその使用
JP7684695B2 (ja) グラム陰性菌に対して活性を有する溶解素ポリペプチド
CN102575240B (zh) 新的细胞内溶素OBPgpLYS
JP7646237B2 (ja) シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定
JP6034187B2 (ja) 抗微生物剤
JP5153943B2 (ja) 抗微生物剤
JP2016208985A (ja) バイオフィルムの低減方法
KR102503567B1 (ko) 신규한 엔돌리신
RU2813626C1 (ru) Модифицированный эндолизин и антибактериальные композиции на его основе для лечения инфекций, вызванных бактериями Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli
RU2807688C9 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
HK40090562A (en) Lysin polypeptides active against gram-negative bacteria
HK40013452B (en) Novel endolysin
HK40013452A (en) Novel endolysin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant